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ABSTRACT 
The brain level of perfluorododecanoic acid (PFDoA) was compared with those of perfluorooctanoic 
acid (PFOA) and perfluorodecanoic acid (PFDA) in rats 9 days after a single oral dose (50 mg/kg). 
The PFDoA level in the brain was 44.0 ± 2.0 [mu]g/g, which was higher than that in the serum (24.4 
± 1.0 [mu]g/ml). By contrast, the concentrations of PFOA and PFDA in the brain were low (<0.8 and 
4.7 ± 0.4 [mu]g/g, respectively), and less than one-tenth of those in the serum. Next, to investigate the 
effects on brain function, the cognitive function alterations of PFOA, PFDA, and PFDoA were 
estimated by the novel object recognition test 5-6 days after dosing. A significant decrease in the 
discrimination index was observed in PFDoA-treated rats while no significant alteration was observed 
in PFDA- and PFOA-treated rats. The effects of PFDoA were further assessed by other behavioral 
tests. PFDoA-associated alteration was observed in the elevated-plus maze test, but not in the Y-maze 
test, open-field test, and forced swim test. A decrease in the discrimination index of the novel object 
recognition test was dependent on the PFDoA dose and the PFDoA concentration in the brain. PFDoA 
concentration in the brain was 28.6 ± 2.6 [mu]g/g 30 days after dosing, and a decrease in 
discrimination index was observed. Taken together, these results suggest that PFDoA distributes in the 
brain easier than PFOA and PFDA and causes cognitive deficit.  
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INTRODUCTION 
 
Perfluoroalkyl substances, including perfluoroalkyl acids (PFAAs) such as perfluorocarboxylic acids 
(PFCAs) and perfluoroalkyl sulfonic acids, have been manufactured and used for a variety of 
industrial applications and consumers products, such as surfactants in fire-fighting foam and cleaning 
agents, protective coatings for textiles, carpets, and electronic and photographic devices, since the 
1950s (Buck et al., 2011; Renner 2001). In addition to direct emission through manufacturing process, 
PFAAs are emitted to the environment as terminal products of the degradation of precursor materials 
such as perfluoroalkyl sulfonamides, perfluoroalkyl telomer alcohols, and fluoropolymers 
(Prevedouros et al., 2006; Wang et al., 2013; Wang et al., 2014). PFAAs are widely spread and found 
in various environmental media, such as air, water, soil, sediment, and sludge from wastewater 
treatment plants (Kim and Kannan, 2007; Lau et al., 2007; Yamashita et al., 2005), since PFAAs are 
highly stable and resistant to biodegradation (Key et al., 1997). In 2001, Giesy and Kannan (2001) 
reported that PFAAs were present in wild life. To date, numerous studies have reported that PFAAs 
bioaccumulate in a wide variety of wild life, not only in industrialized countries but also in the Arctic 
and the Antarctic Oceans (Reiner and Place, 2015). In addition, human biomonitoring studies have 
shown that the general populations in several countries have been exposed to PFAAs (Lau et al., 
2007) and that perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), 
perfluorohexanesulfonic acid, and perfluorononanoic acid have been routinely detected, with PFOS 
levels being highest (Kato et al., 2011).   
Perfluorododecanoic acid (PFDoA), which has chain lengths of 12 carbons, has been reported to 
be found in human serum (Goralczyk et al., 2015); thus, humans are exposed to PFDoA (Gebbink et 
al., 2015). The studies on the toxicity of PFCAs with carbon chain lengths longer than 10 are limited 
(Kato et al., 2015; Liu et al., 2016); therefore, it is necessary to estimate the toxicity of PFDoA. In 
general, PFCAs are thought to distribute predominantly to the blood, liver, and kidney, while having 
limited distribution to the brain in experimental animals (Kudo, 2015). The levels of PFOS and PFOA 
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in the brain are much less than in the serum in experimental animals, indicating that these chemicals 
hardly cross the blood-brain barrier (Mariussen, 2012). The tissue distribution of PFOS and PFOA 
observed in wildlife exhibited similar tendencies. It is noteworthy that the brain concentrations of 
PFCAs with carbon chain lengths longer than 11 were close to those in the serum and liver of marine 
animals (Ahrens et al., 2009; Mariussen, 2012; Rubarth et al., 2011), suggesting that these PFCAs can 
easily pass the blood-brain barrier compared with PFCAs with carbon chain lengths shorter than 10. 
We hypothesize PFDoA passes the blood-brain barrier and affects brain functions. 
Various studies on the toxicities associated with exposure to PFAAs have shown hepatotoxicity 
(Kudo and Kawashima, 2003 a,b), developmental toxicity (Lau et al., 2004; Lau et al., 2007), 
endocrine disrupting effects (Liu et al., 2015, 2016), and immunotoxicity (DeWitt et al., 2012) in 
experimental animals. Compared with these toxic effects, less attention has been paid to the 
neurotoxic potentials. Chronic exposure to PFAAs was associated with small or no effect in adult 
animals (Butenhoff et al., 2009a, 2012; Fuentes et al., 2007c). By contrast, neurobehavioral 
alterations were observed in developmentally exposed animals (Butenhoff et al., 2009b; Fuentes et al., 
2007a,b; Johansson et al., 2008; Onishchenko et al., 2011; Ribes et al., 2010; Viberg et al., 2013). 
The high sensitivity seems to be due to both weak blood-brain barrier and vulnerability to the 
chemicals during the period of high neuronal growth (Eriksson, 1997). It is possible that high 
concentrations of PFAAs lead to alterations in brain functions. 
In the present study, the neurobehavioral effects of PFCAs were estimated in relation to the 
concentrations of them in the brain of adult rats. We found that PFDoA distributed to the brain easier 
than PFOA and PFDA and induced cognitive deficit in adult rats. 
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MATERIALS AND METHODS 
Materials 
PFDoA (>93%) was purchased from Tokyo Chemical Industry, Co. Ltd (Tokyo, Japan). PFOA 
(>98%) and perfluorodecanoic acid (PFDA, >96%) were from Sigma-Aldrich (St. Louis, MO., USA). 
3-Bromoacetyl-7-methoxycoumarin was prepared as described (Ohya et al., 1998). Corn oil was from 
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). All other chemicals were of analytical grade.  
 
Animals and treatments 
All animal procedures were approved by the Institutional Animal Care Committee of Josai University 
in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of 
Japan). Male Wistar rats were purchased from SLC (Hamamatsu, Japan) and were allowed to 
acclimate to the housing facility for at least 1 week prior to treatment. Animals were given free access 
to water and food and were kept in a humidity- and temperature- (23 ± 2[degree]C) controlled 
environment with a 12-h light/dark cycle.  
   Rats aged 8 weeks old were exposed to a single-oral dose of PFDoA at doses of 5, 20, and 50 
mg/kg. A dose of 50 mg/kg was used for comparison of PFOA, PFDA, and PFDoA, since a significant 
alteration was observed with PFDoA at a dose of 50 mg/kg in the novel object recognition test without 
severe weight loss or less activity. All PFCAs were suspended in corn oil (4 ml/kg) and dosed to 
animals. All PFCAs were used without adjusting for the purity of the raw materials since exact purity 
was not given. These animals were subjected to behavioral tests as described below.  
 
Behavioral testing 
Experimental protocols 
   Three sets of experiments were performed, and separate groups of rats were given each test. First 
set of experiments: the animals were divided into six groups (n=5-12), namely vehicle alone, PFDoA 
(5 mg/kg), PFDoA (20 mg/kg), PFDoA (50 mg/kg), PFOA (50 mg/kg), and PFDA (50 mg/kg) and 
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received an oral gavage on day 1. These animals were then tested in a novel object recognition test on 
days 6 and 7. Some of the vehicle- or PFDoA-treated animals underwent the test on days 29 and 30 
(n=5). 
Second set of experiments: the rats which had been treated with vehicle or PFDoA (50 mg/kg) on 
day 1 underwent an open-field test on day 6, followed by a Y-maze test on day 8 (n=10). 
Third set of experiments: the rats which had been treated with vehicle or PFDoA (50 mg/kg) on 
day 1 underwent an elevated-plus maze test on day 7, followed by a forced swim test on days 8-9 
(n=8). 
 
Novel object recognition test 
The novel object recognition test was performed to test for attention and memory in a 
low-motivational state (Galeano et al., 2014). The test was conducted in an opaque plastic enclosure 
(30 cm x 25 cm x 18 cm). The rat was habituated to the apparatus for 30 min 24 h before testing. 
Testing began with a 5 min information phase in the enclosure, where two identical objects (A/A’) 
were placed for the animals to explore. After a resting period of 24 h in the home cage, the animal was 
then placed back in the enclosure, where one familiar object (A) and one novel object (B) were placed, 
and allowed to explore for 5 min (test phase). The test was recorded by a video camera, and the time 
that the snout pointed to each object was estimated as exploration time by two reviewers blinded to 
the conditions of the rats. Between sessions, the objects were cleaned with ethanol followed by water 
to avoid odor cues. The discrimination index was calculated using the following equation: 
Discrimination index = (time spent on novel object – time spent on familiar object)/time spent on both 
novel and familiar objects.  
 
Y-maze test 
The Y-maze test was performed to assess spatial working memory (Galeano et al., 2014). The maze 
consisted of three equal, closed arms (12 cm x 60 cm x 20 cm) connected to the center at equal angles. 
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The rat was placed on the center and allowed to move freely through the maze for 8 min. The test was 
recorded by a video camera, and the number of alternations and the number of arm entries were 
estimated by two reviewers blinded to the conditions of the rats. An arm entry was scored when rats 
placed four paws within the arm. An alternation was defined as an entry into three different arms on 
consecutive choice. The percent alternation was calculated as the ratio of actual to possible 
alternations using the following equation: Alternation (%) = number of alternation/ (number of arm 
entries – 2) x 100. 
 
Elevated plus-maze test  
The elevated plus-maze test was performed to assess anxiety versus risk-taking-like behavior 
(Galeano et al., 2014). The maze consisted of two open arms (10 cm x 50 cm) and two closed arms 
with a wall (10 cm x 50 cm x 40 cm) connected to a central platform (10 cm x 10 cm) to form a cross. 
The maze was elevated to a height of 50 cm from the floor. A video camera was suspended above the 
maze. The rat was placed on the central platform facing an open arm and recorded for a 10 min period 
by a computer-based video tracking system (CompACT VAS/DV, Muromachi Kikai Co., Ltd., Tokyo, 
Japan). The time spent in the open and closed arms of the maze, respectively. The number of entries 
into the open and closed arms were recorded, respectively. Overall locomotor activity was determined 
as the distance traveled in the maze. 
 
Open-field test 
The open-field test was performed to assess locomotor activity and anxiety (Galeano et al., 2014). 
Spontaneous exploratory activity was analyzed using a computer based video tracking system 
(CompACT VAS/DV). A video camera mounted centrally, above the apparatus, monitored a separate 
open field chamber (70 cm x 70 cm x 40 cm, divided into 49 square grids). The computer-defined grid 
lines divided each open field into a center region (30 x 30 cm in the center of the field) and a 
peripheral region. Each rat was placed individually in the open field area for 30 min. Parameters 
7 
 
evaluated included total distance traveled (m), number of crossings, and time spent in the periphery or 
in the center.   
 
Forced swim test 
The forced swim test was performed to assess behavioral despair (Porsolt et al., 1978). The rat was 
placed in a glass cylindrical chamber (20 cm D x 50 cm H) filled with water (30 cm height, 25 ± 
1[degree]C). Two swimming sessions were carried out with an initial 15 min ‘pre-test’ followed by a 5 
min ‘test’ after 24 h. Immobility time, defined as the period during which the animal floats in the 
water with only those movements necessary to keep its head above water, was evaluated by two 
reviewers blinded to the conditions of the rat. 
 
Tissue collection 
Nine days after the oral gavage, the animals were anesthetized with diethyl ether, and blood was 
withdrawn from the inferior vena cava. Then, the whole body was perfused with approximately 300 
ml of ice-cold saline from the left ventricle to remove the blood. The brain and liver were quickly 
removed, weighed, frozen in liquid nitrogen, and stored at -80[degree]C until use. Serum was 
prepared by centrifugation and stored at -30[degree]C until analysis. Some rats were sacrificed 30 
days after dosing, and serum and tissue samples were obtained as described above. The liver and the 
brain were homogenized with 9 volumes of 0.25 M sucrose, 1 mM EDTA, and 10 mM Tris-HCl 
(pH7.4). A portion of the homogenate was subjected to PFCA analysis.  
 
Analysis of PFCAs 
The concentrations of PFCAs in the serum and tissue samples were determined as described 
previously (Ohya et al., 1998). For determination of PFOA, PFDA, and PFDoA, a known amount of 
perfluorohexanoic acid, PFOA, and PFDA was added to the samples as internal standards, 
respectively, prior to extraction. In brief, PFCAs were extracted with ethyl acetate:hexane (1:1, v/v) 
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from an aliquot of serum or tissue homogenates as an ion pair with tetrabutylammonium after adding 
an internal standard. The extract was then incubated with 3-bromoacetyl-7-methoxycoumarin to yield 
acetylmethoxycoumarin derivatives of PFCAs. The reaction mixture was separated with high 
performance liquid chromatography with a fluorescence detector. 
 
Statistical analysis 
All data are expressed as means ± SEM. For comparison of dose (0, 5, 20 and 50 mg/kg) and different 
PFCAs (control, PFOA, PFDA and PFDoA), one-way analysis of variance followed by Scheffé’s 
multiple-range test was used as a post-hoc test. For evaluation of the difference in Y-maze test, 
open-field test, elevated-plus maze test and forced swim test, the statistical significance between 
control and PFDoA-treated rats was estimated by the Student’s t-test. The threshold for assessing 
significance was P<0.05, 2-tailed. 
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RESULTS 
 
Body weights, organ weights, and tissue concentration of PFCAs 
Body weights are shown in Table 1 on day 10 for control, PFOA-, PFDA-, and PFDoA-treated rats 
(50 mg/kg body weight). Body weight in the PFDA group was significantly less than in the control, 
and those of the PFDoA group were slightly less than the control (Table 1). Hepatomegaly was 
observed in all PFCA-treated groups (Table 1). The serum concentration of PFDoA was less than 
those of PFDA and PFDoA (Table 1). The hepatic concentration of PFDoA was comparative to that of 
PFDA and 4.2 times higher than PFOA (Table 1). The PFDoA concentration in the brain was greater 
than that of the serum, whereas the PFOA and PFDA concentrations were less than 5 [mu]g/g brain 
(Table 1). 
 
Effects of PFCA on memory function 
To assess attention and memory in a low motivational state, the novel object recognition test was 
performed. In the information phase, no significant difference was observed in exploration time 
between two identical objects in all test groups on day 6 (Fig. 1A). In the test phase, rats in the vehicle, 
PFOA, and PFDA groups preferred the novel object over the familiar object, whereas PFDoA-treated 
rats did not (Fig. 1B). The discrimination index was not altered in PFOA-treated rats, slightly, but not 
significantly, declined in PFDA-treated rats, and greatly declined in PFDoA-treated rats (Fig. 1D). 
The total exploration time was not different between the four experimental groups (Fig. 1C). 
The Y-maze test was also employed to assess spatial and working memory. No significant 
difference was observed in the percentage of alternation behavior and total arm entries between 
PFDoA-treated rats and vehicle-treated rats (Table 2).  
 
Effects of PFDoA on anxiety behavior 
The effects of PFDoA were estimated by the open-field test. No significant differences were observed 
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in the mean distance traveled, the number of crossings, or the time spent in the central area between 
vehicle- and PFDoA-treated rats (Table 2). 
The effects of PFDoA on anxiety was estimated by the elevated-plus maze test. The treatment 
with PFDoA significantly increased the time spent in the open arms (Fig. 2A), while the distance 
traveled, the total number of arm entries, and the percentage of open arm entry were not altered by the 
treatment with PFDoA (Fig. 2B-D). 
 
Effects of PFDoA on depressive-like behavior 
     In the forced-swim test, immobility time, which indicates a despair-like state, was not affected 
by the treatment with PFDoA (Table 2). 
 
Dose-dependency and duration of PFDoA-induced memory deficit 
The dose dependency of the PFDoA-induced decrease in the discrimination index was estimated in 
the novel object recognition test. A decrease in the discrimination index was observed at the doses 
over 20 mg/kg (Fig. 6B), while the total exploration time was unchanged at any dose (Fig. 3A). The 
concentration of PFDoA increased in both the serum and brain as the dose of PFDoA increased (Fig. 
3C). The relationship between the concentration of PFDoA in the brain and the discrimination index 
revealed that a decrease in the discrimination index was observed when the PFDoA concentration was 
more than 20 [mu]g/g tissue (Fig. 3D). Memory deficit in the novel object recognition test was 
observed on day 30 after an administration of PFDoA (Fig. 4B), while the total exploration time was 
not altered (Fig. 4A). The PFDoA concentrations in the serum and brain at 30 days after dosing were 
approximately 70% of those at 9 days after dosing (Fig. 4C). The body weight of PFDoA-treated rats 
was 355.8 ± 8.3 g, which was slightly less than that of the control rats (379.8 ± 8.3 g, P<0.05).  
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DISCUSSION 
In the present study, we demonstrated that PFDoA is highly accumulated in the brain of adult rats that 
have received a single oral dose. This is different from PFOA and PFDA. PFDoA may distribute 
equally in the brain, since PFDoA concentrations of various parts in the brain were not different one 
another when rats were fed a diet admixed with 0.05% (w/w) PFDoA for 7 days (data not shown). To 
date, PFAAs were thought to accumulate primarily in protein-rich tissues, such as the liver and blood 
(Kudo, 2015), with little distribution in the brain (Mariussen, 2012). Several studies have revealed 
that the levels of PFAAs in the brain were lower than those in the liver and serum, indicating that 
most PFAAs have limited access to the brain. In adult rats, the levels of PFOS, PFOA, and 
perfluorononanoic acid were shown to be approximately 1-3% of those in the serum at low doses 
(Austin et al., 2003; Benskin et al., 2009; Kudo et al., 2007). PFOS levels in the brain were more than 
10% of those in the serum when rats were exposed to a sublethal dose of PFOS (Austin et al., 2003; 
Cui et al., 2009). In the latter case, the high permeability of the brain to PFOS is thought to be due to 
membrane perturbation by high concentrations of PFOS in the serum (Wang et al., 2011). In studies of 
the tissue distribution of PFAA in wildlife, the brain levels of PFAA were lower than those in the 
serum (Mariussen, 2012), except for PFDoA and perfluorotricosanoic acid of which the levels in the 
brain were equal and higher than those in the serum, respectively (Ahrens et al., 2009; Rubarth et al., 
2011). These observations on PFDoA are in accordance with the present results. The mechanism 
underlying the high distribution of PFDoA to the brain remains to be solved. Although the logKow of 
PFDoA is not available experimentally, it was predicted to be 6.30, 8.23, and 10.16 for PFOA, PFDA, 
and PFDoA, respectively, by EPI suite software (Bhhatarai and Gramatica, 2011). The high 
lipophilicity may be responsible for the high distribution of PFDoA to the brain.  
    The neurotoxic effects of PFAAs, especially PFOS and PFOA, were estimated in several studies 
and summarized by Mariussen (2012). Most studies have shown developmental neurotoxicity, such as 
delays in neuromotor development, when animals were exposed to the chemicals prenatally or during 
the neonatal period (Mariussen, 2012). A weak blood brain barrier is thought to be responsible for the 
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high sensitivity of developing animals. By contrast, studies on neurotoxicity in adult animals are 
limited. Butenhoff et al. (2009a) reported that repeated doses of perfluorohexanesulfonic acid 
exhibited no effects on the functional observational battery or on motor activity. Butenhoff et al. 
(2012) have shown that perfluorobutyric acid (PFBA) exhibited no effect on hearing, static righting, 
grip strength, or motor activity in adult rats that received oral gavages at doses of 30 and 150 
mg/kg/day for 28 or 90 days. A delayed direct bilateral pupillary reflex was observed in male rats that 
chronically received PFOA at a dose of 30 mg/kg/day and PFBA at a dose of 150 mg/kg (Butenhoff et 
al., 2012). In the study by Fuentes et al. (2007c), oral exposure to PFOS for 4 weeks exhibited no 
effect in a functional observation battery, and small effects were observed at doses of 3 or 6 
mg/kg/day in the open field test and Morris water maze test, although dose-dependency was not 
observed. The levels of PFAAs in brain might be low although the levels were not available in these 
studies. By contrast, the present study demonstrated that treatment with PFDoA was associated with a 
significant cognitive deficit in adult rats, and that the effect continued for at least 4 weeks after dosing. 
It seems likely that the magnitude of the cognitive deficit is dependent on the concentration of PFDoA 
in the brain for the following reasons: i) an inverse relationship was observed between the 
concentration of PFDoA in the brain and the discrimination index (Fig. 3D); ii) the decrease in the 
discrimination index was observed 30 days after dosing, when the concentration of PFDoA in the 
brain remained high (Fig. 4); iii) PFOA, the level of which was less than 0.8 [mu]g/g, did not alter the 
recognition index, and PFDA slightly, but not significantly, decreased the recognition index and was 
found in the brain (4.7 [mu]g/g, Table 1).  
    To assess the neurotoxic effects of PFDoA, 5 behavioral tests were employed in the present 
study: the novel object recognition test and Y-maze test to assess cognitive function, the open-field 
test and elevated-plus maze test to assess anxiety, and the forced swim test to assess depression. 
Treatment of PFDoA was associated with a significant deficit in novel object recognition tests (Fig. 1), 
while no significant difference was observed between the control and PFDoA-treated rats in Y-maze 
tests (Table 2). It seems likely that the novel object recognition test is more sensitive to neurotoxic 
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substances compared with the Y-maze test (Tian et al., 2010, Ogundele et al., 2014). PFDoA may not 
be strong enough to cause effects in the Y-maze test. Our results also suggested that PFDoA slightly 
decreased anxiety in the elevated plus-maze test (Fig. 2), while no significant effect was observed in 
the open-field test (Fig. 2). Although both the open-field test and the elevated-plus maze test assess 
anxiety-like behavior, these tests operationalize different aspect of emotional behavior (Ramos, 2008). 
Alteration with PFDoA treatment may reflect a specific dimension of emotional behavior linked to the 
elevated-plus maze test. By contrast, PFDoA did not induce depression-like behavior (Table 2).  
    The mechanisms underlying the cognitive deficit associated with PFDoA treatment remains to be 
solved. Several in vitro studies have proposed mechanisms underlying neurobehavioral alterations 
associated with PFAAs. It has been shown that PFOS has a modulating effect on ion currents in 
cerebellar Purkinje cells (Harada et al., 2006) and in primary cultured hippocampal neurons (Liao et 
al., 2009). PFOS has been shown to alter Ca2+ currents and increase the amplitude of field excitatory 
postsynaptic potentials in the CA1 region of hippocampal slices (Liao et al., 2008). Liu et al. (2011) 
demonstrated that PFOS induced a disturbance of Ca2+ homeostasis in hippocampal neurons. Ca2+ is 
involved in the synaptic processes underlying both learning and memory, and the perturbation of Ca2+ 
homeostasis interferes with physiological processes in neurons, including synaptic activity (Baker et 
al., 2013; Berridge et al., 1998). PFDoA, like other PFAAs, may disturb Ca2+ homeostasis in the 
brain. 
    In conclusion, the present study demonstrated that PFDoA passes through the blood-brain barrier 
and accumulates in the brain. Cognitive deficit is associated with PFDoA levels in the brain. 
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FIGURE LEGENDS 
 
Fig. 1 
Effects of PFOA, PFDA, and PFDoA on the novel object recognition test. Rats received an oral 
gavage of PFOA, PFDA, or PFDoA at a dose of 50 mg/kg, and the test was performed on days 6-7. A, 
Exploration time of object A and object A’ in the information phase. B, Exploration time of object A 
and object B in the test phase. C, Total exploration time in the test phase. D, Discrimination index. 
Values represent means ± SEM (control, 12; PFOA, 4; PFDA, 7; PFDoA, 7). * Difference compared 
with object A (P<0.05). a-c, Significant difference without a common superscript (P<0.05).   
 
Fig. 2 
Effects of PFDoA on the elevated-plus maze test. Rats received an oral gavage of PFDoA at a dose of 
50 mg/kg, and the test was performed on day 7. A, Time spent in open arms. B, Percentage of open 
arm entries to total arm entries. C, Distance traveled in overall maze. Values represent means ± SEM 
(control, 6; PFDoA, 8). * Difference compared with control (P<0.05). 
 
Fig. 3 
Dose dependency of the effect of PFDoA on the novel object recognition test. Rats received an oral 
gavage of PFDoA at doses of 5, 20, or 50 mg/kg, and the test was performed on days 6-7. A, Total 
exploration time in the test phase. B, Relationship between dose and discrimination index. C, PFDoA 
concentrations in the serum and the brain on day 10. D, Relationship between PFDoA concentration in 
the brain and discrimination index. Values represent means ± SEM (control, 12; 5 mg/kg, 5; 20 mg/kg, 
5; 50 mg/kg, 7). * Difference compared with serum (P<0.05). a-c, Significant difference without a 
common superscript (P<0.05).   
 
Fig. 4 
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Effect of PFDoA on the novel object recognition test on day 30. Rats received an oral gavage of 
PFDoA at a dose of 50 mg/kg, and the test was performed on days 29-30. A, Total exploration time in 
the test phase. B, Discrimination index. C, PFDoA concentrations in the serum and the brain on day 9 
and day 31. Values represent means ± SEM (n=5). * Difference compared with control (P<0.05). # 
Difference compared with the value on 10 day (P<0.05).  
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Table 1  Body weight, tissue weight, and PFCA concentrations after oral administration of PFCA. 
 
  Vehicle PFOA PFDA PFDoA 
Body weight              
   Initial (g) 261.1 ± 2.6 254.8 ± 1.2 259.9 ± 1.9 258.0 ± 2.9 
   Final (g) 294.0 ± 2.9a 288.6 ± 0.9ab 239.3 ± 4.4c 276.4 ± 3.8b 
   Weight gain (g) 32.9  1.5a 33.9  1.3a -20.6  4.1b 18.4  3.3c 
              
Tissue weight              
   Liver (g) 11.22 ± 0.26a 17.13 ± 0.87b 15.65 ± 0.69b 15.47 ± 0.60b 
    (% of body weight) 3.82  0.09a 5.93  0.30bc 6.52  0.21c 5.58  0.17b 
   Brain (g) 1.96 ± 0.02 1.92 ± 0.02 1.92 ± 0.01 1.94 ± 0.02 
 (% of body weight) 0.67  0.01a 0.66  0.01ab 0.80  0.01c 0.70  0.01b 
              
PFCA concentration              
   Serum ([micro]g/ml) - 33.3 ± 4.4a 43.0 ± 1.3b 24.4 ± 1.0c 
   Liver ([micro]g/g tissue) - 58.7 ± 8.1a 287.7 ± 11.4b 247.7 ± 9.8c 
   Brain ([micro]g/g tissue) - NDa 4.7 ± 0.4a 44.4 ± 2.0b 
  Brain/serum  - 0.000 ± 0.000a 0.109 ± 0.008a 1.821 ± 0.059b 
  Liver/serum  - 1.774 ± 0.124a 6.726 ± 0.301b 10.315 ± 0.545c 
   Rats were received an oral gavage of PFOA, PFDA or PFDoA at a dose of 50 mg/kg, or vehicle alone. Blood and tissues were collected on day 10 
after dosing. Values represent the mean ± SEM (control, 12; PFOA, 4; PFDA, 7; PFDoA, 7). (-), not determined; ND, less than detection limit (0.8 
[micro]g/g). a, b, c Means without a common superscript are a significantly different (P<0.05). In the absence of superscript, the means are not statistically 
significant. 
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Table 2   Effects of PFDoA on the Y-maze test, open field test, and forced swim test 
Control PFDoA P value 
Y-maze test 
    Alternations (%) 65.5 ± 5.6 75.7 ± 5.1 0.194 
    Total arm entries 16.4 ± 1.6 14.0 ± 2.0 0.362 
Open-field test 
    Distance traveled (m) 20.3 ± 2.3 16.5 ± 1.5 0.189 
    Number of crossings 399.1 ± 32.1 322.2 ± 36.4 0.131 
    Time spent in center region (%) 1.67 ± 0.23 1.44 ± 0.31 0.566 
Forced swim test 
    Immobility time (s) 165.9 ± 21.9 156.8 ± 11.6 0.718 
   Rats received an oral dose of PFDoA at a dose of 50 mg/kg. The Y-maze test (n=8), open-field test (n=10) 
and forced swim test (n=8) were performed on day 8, day 6, and day 8-9, respectively. The difference was not 
significant. 
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